MAGE-A proteins are testis-specific E3 ubiquitin ligase components whose expression is upregulated in many cancers. MAGE-A3 and -A6 act as oncogenes and recent work now shows that they degrade the central metabolic regulator AMPK, providing a novel mechanism for rewiring cancer metabolism.
AMP-activated protein kinase (AMPK) is a serine/threonine kinase that is activated under conditions of low cellular energy, such as those that accompany loss of nutrients, particularly glucose and oxygen. AMPK plays a highly conserved role as an energy sensor and acts to restore metabolic homeostasis on a cellular and ultimately organismal level by downregulating anabolic biosynthetic ATP-consuming processes, like protein and lipid biosynthesis, and upregulating catabolic ATP-restoring processes, like autophagy and fatty acid oxidation. As such, AMPK is one of the central metabolic regulators that dominantly impacts overall metabolic state across most cell types and tissues studied to date in all eukaryotes [1] .
AMPK has also been linked with cancer, being one of the best-studied substrates of the LKB1 tumor suppressor, which is inactivated in 25% of lung adenocarcinomas and is the single gene responsible for the inherited cancer predisposition disorder Peutz-Jeghers syndrome [2] . There are two catalytic AMPK genes in mammals, AMPKa1 and AMPKa2, and LKB1 directly phosphorylates and stimulates the kinase activity of both. Thus, most tumors and cell types in which LKB1 is mutated can no longer activate AMPK in response to metabolic stress. The role of AMPK in maintaining metabolic homeostasis also accounts for its requirement for cell survival after a number of metabolic insults, including tumor cells in different contexts [3] . This potential dual nature of the role of AMPK in cancer has been noted in many cellular and xenograft contexts but remains to be critically analyzed in autochthonous mouse models of cancer.
While phosphorylation of the activation loop threonine of AMPK (Thr172 in human AMPKa2) has been thoroughly studied as the central post-translational modification required for AMPK activation, less is known about how other post-translational modifications of AMPK subunits modulate AMPK function. In the past decade, evidence for inhibitory phosphorylation at the carboxyl terminus of AMPKa proteins has been accumulating and AMPK has been reported to be acetylated and glycosylated in response to various nutrient-excess conditions [4] . In contrast, much less attention has been paid to the regulated degradation of AMPK, which is surprising given how the central nodes of signaling pathways -such as AMPK -are often regulated by all possible mechanistic avenues.
Coming from an entirely distinct focus of trying to decode the targets for E3 ubiquitin ligase complexes, Potts and colleagues [5] now report the identification of the genes MAGE (melanoma antigen genes)-A3 and MAGE-A6 as being critical regulators of AMPK turnover. The remarkable feature of MAGE-A3/6 is that RNA sequencing reveals that their normal tissue expression is exquisitely restricted to the testis in mice and humans. However, as their name implies, these genes are highly expressed in the majority of melanomas analyzed, as well as in lung squamous and adenocarcinomas, and in head and neck and colorectal tumors amongst others. Knockdown of these two highly related genes resulted in loss of cell viability in a number of cancer cell lines bearing their expression [5] . Conversely, enforced overexpression of MAGE-A6 in cancer cells lacking MAGE-A3/6 expression or in immortalized but non-transformed NIH3T3 cells or human colonic epithelial cells was sufficient to promote foci formation and anchorage-independent growth on a scale similar to or greater than that induced by classic oncogenes, e.g. an activated KrasV12 mutant [5] .
Previously, Potts and colleagues discovered that the MAGE family of proteins acts to scaffold members of the large TRIM family of E3 ubiquitin ligases to their substrates [6] . In particular, the testis-specific MAGE proteins MAGE-A2, A3, A6, and C2 were found to be upregulated in cancer and all bind to TRIM28, also known as KAP1 or TIF-1beta. TRIM28 is also overexpressed in certain cancers, and Potts and colleagues [6] previously reported that the MAGEA3/6-TRIM28 complex induces the degradation of the tumor suppressor p53. The regulation of a p53 ortholog by a TRIM28 ortholog is conserved back to Drosophila and is likely to play a role in the function of the MAGE-A3/6 proteins in some cancers [7] . However, several cell lines in which MAGE-A2/3 have been shown to be essential for cell viability are p53-null, suggesting that additional targets of TRIM28 in cancer may exist [5] . Taking advantage of protein microarrays bearing >9,000 baculovirally produced recombinant proteins, Potts and colleagues [5] now demonstrate that AMPKa1 is one of the most robust substrates degraded by TRIM28.
Consistent with that finding, knockdown of MAGE-A3/6 or TRIM28 resulted in a robust increase in total AMPKa1 and activated phospho-Thr172 AMPKa1. Activation of AMPK via loss of MAGE-A3/A6 or TRIM28 resulted in increased phosphorylation of AMPK substrates like acetyl coenzyme A carboxylase and ULK1 (Unc51-like kinase 1), as well as expected increases in autophagy and suppression of mammalian target of rapamycin (mTOR) [5] . Rewiring of metabolism towards an mTOR-dependent, pro-growth, glycolytic pathway has been observed with AMPK deficiency in other settings where AMPK appears to behave as a classic tumor suppressor whose loss promotes cancer [8] . Thus, it appears that the cancer-specific upregulation of MAGE-A3/A6, and possibly other MAGE family members, triggers ubiquitination and degradation of AMPKa1, promoting tumorigenesis. This makes the inactivation of AMPK signaling a common event shared by LKB1-mutant cancers and tumors overexpressing MAGE-A3/A6 (Figure 1 ).
Upon examination of these findings in human tumor samples, a correlation between MAGE-A3/A6 mRNA expression and loss of total and phospho-AMPKa was observed in colon, breast, and lung cancers. MAGE-overexpressing cancer cell lines also displayed heightened sensitivity to AMPK agonists, which include direct allosteric activators, like A769662, in addition to metabolic agents like AICAR and the widely prescribed diabetes therapeutic metformin [5] . This indicates that patients with tumors expressing MAGE-A mRNAs may have potential therapeutic opportunities with AMPK agonists.
Interestingly, increased expression of MAGE-A proteins has also been observed to play a critical role in specific cancer contexts. Studies of estrogen receptor positive (ER + ) breast cancers and their therapeutic response to tamoxifen revealed that tamoxifen-resistant clones uniquely upregulate MAGE-A2, and MAGE-A2 expression alone was sufficient to confer resistance to tamoxifen in multiple models [9] . Further to this new finding of a cancer-specific gene promoting AMPKa1 ubiquitination and degradation, which particular E3 ligases promote this process in normal tissues? Could TRIM28 partner with other MAGE proteins or other scaffolds to promote AMPKa1 or AMPKa2 turnover in non-cancerous conditions and in the testis? It is notable that another TRIM protein, TRIM32 (which is not in the same three-member TIF subfamily of TRIMs as TRIM28), was previously shown to promote AMPKa1 ubiquitination in vitro, though this effect appeared non-specific and was not examined in vivo [10] . This does, however, raise the possibility that other TRIM family members may dictate AMPKa turnover in other settings. It would be particularly interesting to examine in metabolic contexts where AMPK activity may be adaptively downregulated, whether E3 ligases or E3 ligase adaptors are transcriptionally induced under conditions of metabolic excess to target AMPK or other parts of the AMPK pathway for degradation.
While the MAGE-A3/6-TRIM28 complex targets AMPKa1, another E3 ubiquitin ligase named WWP1, a member of the HECT-domain family, was recently reported to specifically target AMPKa2. Notably WWP1 was found to degrade AMPKa2 under high-glucose conditions when AMPK is known to be functionally inactive, such as in C2C12 cells in high glucose or in db/db mouse models of insulin resistance and obesity-induced diabetes [11] . Like TRIM28-mediated regulation of p53 and ZNF transcription factor turnover [12, 13] , the previously described targets for WWP1 were SMADs, KLF family transcription factors and members of the p53 family [14] . It will be particularly interesting to further define the contexts in which WWP1 or other E3 ligases control the rapid degradation of AMPKa1 and AMPKa2 proteins, and to identify the other proteins that are co-degraded by these same E3 ligases. This mechanism of coordinated rapid turnover of critical central regulators by a common E3 ligase could be a mechanism for acute (and adaptive) metabolic changes. Gaining a more thorough understanding of which particular E3 ligases mediate AMPK turnover, in which contexts, and what else is simultaneously targeted for destruction may provide novel therapeutic opportunities for cancer and a host of other metabolic disorders. Figure 1 . Cancer cells upregulate E3 ligase complex components to stimulate TRIM28-dependent degradation of p53 and AMPK.
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In normal cells, the tumor suppressors p53 and LKB1 restrict growth. LKB1 does so in part via activating AMPK to inhibit the mTOR complex 1 (mTORC1) and promote autophagy. In some cancer cells, the normally testes-specific ubiquitin ligase scaffold proteins MAGE-A3 and -A6 get induced and now recruit their binding partner, the E3 RING-domain ubiquitin ligase TRIM28, to its substrates AMPKa1 and p53. This results in the ubiquitin-dependent degradation of both p53 and AMPKa1, causing loss of autophagy and hyperactivation of mTORC1. In other tumor settings, such as lung adenocarcinomas, a significant fraction of tumors acquire inactivating mutations in both p53 and LKB1, functionally mimicking the action of MAGE-A3/A6 upregulation to block those two tumor suppressor pathways.
